Cabozantinib for Advanced Renal Cell Carcinoma – Details


( Last Updated : January 25, 2018)
Generic Name:
Cabozantinib
Project Status:
Withdrawn
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
PC0123-000

Details

Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma (RCC)
Funding Request:
For the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior therapy
Review Status:
Withdrawn
Pre Noc Submission:
Yes
Sponsor:
Ipsen Biopharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
Clarification:
Ipsen Biopharmaceuticals Canada Inc. has notified pCODR that the Category 2 submission requirements for the pre NOC submission of Cabozantinib (Cabometyx) RCC cannot be met at this time. As per pCODR Procedures C3.1.6, the pCODR program has stopped the review.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.